AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Cardinal Health, AutoNation, Target, Avnet and ABM Industries among top broker-loved stocks amid Q4 earnings season
ByAinvest
Thursday, Jan 29, 2026 12:17 pm ET1min read
ABM--
AN--
AVT--
CAH--
TGT--
The Q4 earnings season is off to a strong start with 76.4% of S&P 500 participants beating EPS estimates and 63.2% surpassing revenue estimates. To find broker-loved stocks, we screened for companies with improving broker recommendations and upward revisions in earnings estimates over the past four weeks. The top 5 stocks are Cardinal Health, AutoNation, Target Corporation, Avnet, and ABM Industries. These stocks have seen net upgrades, earnings estimate revisions, and meet other screening criteria such as a low price-to-sales ratio, significant average daily volume, and a high market value.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet